Showing results (151-160 of 196) with videos related to

Sort By:
Pageof 20
Lancet (London, England)|January 13, 2015
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials, Jordan Fulcher, Rachel O'Connell, et al.
Diabetes/Metabolism Research and Reviews|November 1, 2019
In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose toleranceFrancesca Santilli, Francesco Zaccardi, Rossella Liani, et al.
Circulation|November 27, 2002
Increased oxidative stress and platelet activation in patients with hypertension and renovascular diseasePietro Minuz, Paola Patrignani, Stefania Gaino, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 15, 2024
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
European Heart Journal|December 8, 2022
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on ThrombosisFelicita Andreotti, Tobias Geisler, Jean-Philippe Collet, et al.
Circulation|November 1, 2017
Mechanisms, Consequences, and Prevention of Coronary Graft FailureMario Gaudino, Charalambos Antoniades, Umberto Benedetto, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 29, 2019
Platelet-Specific Deletion of Cyclooxygenase-1 Ameliorates Dextran Sulfate Sodium-Induced Colitis in MiceAngela Sacco, Annalisa Bruno, Annalisa Contursi, et al.
European Heart Journal|March 21, 2025
2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations I: therapy and preventionPeter Jüni, Sotiris Antoniou, Elena Arbelo, et al.
The Lancet. Diabetes & Endocrinology|October 13, 2025
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysisWilliam G Herrington, Zhaojing J Che, Rebecca Sardell, et al.
Eclinicalmedicine|July 21, 2025
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trialJunwen Zhou, Claire Williams, Natalie Staplin, et al.
Pageof 20